Victory Capital Management
ITOS

Victory Capital Management’s iTeos Therapeutics ITOS Stock Holding History

Victory Capital Management’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-102,188
Closed -$610K – 2512
2025
Q1 		$610K Buy
102,188
+429
+0.4% +$3.15K ﹤0.01% 1976
2024
Q4 		$782K Buy
101,759
+6,519
+7% +$56K ﹤0.01% 1906
2024
Q3 		$972K Sell
95,240
-15,149
-14% -$231K ﹤0.01% 1787
2024
Q2 		$1.64M Buy
110,389
+16,629
+18% +$238K ﹤0.01% 1499
2024
Q1 		$1.28M Buy
93,760
+13,967
+18% +$152K ﹤0.01% 1619
2023
Q4 		$874K Sell
79,793
-19,340
-20% -$192K ﹤0.01% 1781
2023
Q3 		$1.09M Buy
99,133
+351
+0.4% +$4.49K ﹤0.01% 1610
2023
Q2 		$1.31M Buy
98,782
+14,333
+17% +$204K ﹤0.01% 1543
2023
Q1 		$1.15M Buy
84,449
+20,857
+33% +$374K ﹤0.01% 1620
2022
Q4 		$1.24M Buy
63,592
+3,636
+6% +$71.1K ﹤0.01% 1618
2022
Q3 		$1.14M Buy
59,956
+4,845
+9% +$112K ﹤0.01% 1669
2022
Q2 		$1.14M Buy
55,111
+10,591
+24% +$251K ﹤0.01% 1683
2022
Q1 		$1.2M Buy
+44,520
New +$1.62M ﹤0.01% 1712

Other funds holding ITOS

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Victory Capital Management's ITOS Position: Q2 2025 in Review

Victory Capital Management sold out of iTeos Therapeutics (ITOS) in Q2 2025, closing a stake of 102,188 shares — an estimated $610K sold.

Victory Capital Management first reported a position in ITOS in Q1 2022 and held it in 13 quarters. The position peaked at $1.64M in Q2 2024. 136 funds tracked by Wall St. Rank hold ITOS as of Q2 2025.

  • Victory Capital Management reported no remaining iTeos Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Victory Capital Management sold 102,188 iTeos Therapeutics shares in Q2 2025, an estimated $610K.
  • Victory Capital Management first reported a position in iTeos Therapeutics in Q1 2022 and held it in 13 quarters.
  • Victory Capital Management's iTeos Therapeutics position peaked at $1.64M in Q2 2024.
  • 136 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2025.

Based on Victory Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.